JP2015529802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529802A5 JP2015529802A5 JP2015521863A JP2015521863A JP2015529802A5 JP 2015529802 A5 JP2015529802 A5 JP 2015529802A5 JP 2015521863 A JP2015521863 A JP 2015521863A JP 2015521863 A JP2015521863 A JP 2015521863A JP 2015529802 A5 JP2015529802 A5 JP 2015529802A5
- Authority
- JP
- Japan
- Prior art keywords
- nachr
- flna
- amount
- hydrocarbyl
- tlr4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 claims description 53
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 claims description 53
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 32
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 21
- 230000007792 alzheimer disease pathology Effects 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 238000000034 method Methods 0.000 claims 41
- 102000004169 proteins and genes Human genes 0.000 claims 39
- 108090000623 proteins and genes Proteins 0.000 claims 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 25
- 229910052757 nitrogen Inorganic materials 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 12
- 102000005962 receptors Human genes 0.000 claims 12
- 108020003175 receptors Proteins 0.000 claims 12
- 239000001301 oxygen Substances 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 208000024827 Alzheimer disease Diseases 0.000 claims 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 9
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims 9
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 239000011593 sulfur Substances 0.000 claims 9
- -1 C-1 compound Chemical class 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 7
- 238000005259 measurement Methods 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical group CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 2
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 102000013366 Filamin Human genes 0.000 claims 2
- 108060002900 Filamin Proteins 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000002764 solid phase assay Methods 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- SEJUQQOPVAUETF-QHLBDZCJSA-N (2r,6r,11s)-3-(cyclopropylmethyl)-6-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2h)-one Chemical compound C([C@@]1([C@@H]([C@@H]2C(=O)C=3C1=CC(O)=CC=3)C)CC)CN2CC1CC1 SEJUQQOPVAUETF-QHLBDZCJSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229950002494 diprenorphine Drugs 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- AKXCFAYOTIEFOH-XTNAHFASSA-N n-[(e)-[(4r,4as,7ar,12bs)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ylidene]amino]benzamide Chemical compound C1(/[C@H]2[C@]34CCN(CC=C)[C@@H]([C@@]4(CC1)O)CC1=CC=C(C(O2)=C13)O)=N\NC(=O)C1=CC=CC=C1 AKXCFAYOTIEFOH-XTNAHFASSA-N 0.000 claims 1
- 229960000805 nalbuphine Drugs 0.000 claims 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 1
- 229960000938 nalorphine Drugs 0.000 claims 1
- AJPSBXJNFJCCBI-YOHUGVJRSA-N naloxonazine Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 AJPSBXJNFJCCBI-YOHUGVJRSA-N 0.000 claims 1
- 229960004127 naloxone Drugs 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 claims 1
- 102100026561 Filamin-A Human genes 0.000 description 4
- 101000913549 Homo sapiens Filamin-A Proteins 0.000 description 4
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671445P | 2012-07-13 | 2012-07-13 | |
| US61/671,445 | 2012-07-13 | ||
| US201361789180P | 2013-03-15 | 2013-03-15 | |
| US61/789,180 | 2013-03-15 | ||
| PCT/US2013/050368 WO2014012054A1 (en) | 2012-07-13 | 2013-07-12 | Alzheimer's disease assay in a living patent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019139317A Division JP6796168B2 (ja) | 2012-07-13 | 2019-07-30 | 生きている患者でのアルツハイマー病アッセイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015529802A JP2015529802A (ja) | 2015-10-08 |
| JP2015529802A5 true JP2015529802A5 (OSRAM) | 2016-09-01 |
| JP6566867B2 JP6566867B2 (ja) | 2019-08-28 |
Family
ID=49914282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521863A Active JP6566867B2 (ja) | 2012-07-13 | 2013-07-12 | 生きている患者でのアルツハイマー病アッセイ |
| JP2019139317A Active JP6796168B2 (ja) | 2012-07-13 | 2019-07-30 | 生きている患者でのアルツハイマー病アッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019139317A Active JP6796168B2 (ja) | 2012-07-13 | 2019-07-30 | 生きている患者でのアルツハイマー病アッセイ |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US9354223B2 (OSRAM) |
| EP (1) | EP2872899B1 (OSRAM) |
| JP (2) | JP6566867B2 (OSRAM) |
| WO (1) | WO2014012054A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016022605A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP6463162B2 (ja) * | 2015-02-10 | 2019-01-30 | キヤノン株式会社 | 記録制御装置、記録制御方法、及びプログラム |
| AU2016281897A1 (en) * | 2015-06-26 | 2018-01-25 | Bisio Progetti S.P.A. | Single-dose capsule for the preparation of beverages |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| JP7034152B2 (ja) | 2016-10-05 | 2022-03-11 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 小分子ａｍｐｋ活性化剤 |
| BR112019014688A2 (pt) | 2017-01-20 | 2020-02-18 | Pfizer Inc. | Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl |
| JP2020506903A (ja) | 2017-01-23 | 2020-03-05 | ファイザー・インク | Ｍａｇｌ阻害薬としての複素環式スピロ化合物 |
| WO2019089066A1 (en) * | 2017-11-06 | 2019-05-09 | Acelot, Inc. | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO Aβ42 OLIGOMER FORMATION |
| US12186307B2 (en) | 2019-02-13 | 2025-01-07 | Yale University | Methods of treating epilepsy |
| BR112021016622A2 (pt) * | 2019-02-21 | 2021-11-03 | Pain Therapeutics Inc | Polimorfos sólidos de um composto de ligação de flna e seus sais de cloridrato |
| WO2020178447A1 (en) * | 2019-03-06 | 2020-09-10 | LDN Pharma Limited | Method for determining efficacy |
| EP4027987A4 (en) | 2019-09-10 | 2023-11-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Methods and materials for increasing level of phosphorylated ampk protein |
| IL302531A (en) * | 2020-11-03 | 2023-07-01 | Cassava Sciences Inc | Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4 |
| EP4374175A4 (en) * | 2021-07-23 | 2025-08-20 | Cassava Sciences Inc | DOSAGE OF COMPONENT FOR ALZHEIMER'S DISEASE IN A LIVING SUBJECT |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1220440B (de) | 1962-02-14 | 1966-07-07 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| JP4340386B2 (ja) * | 1997-08-28 | 2009-10-07 | ノバルティス アクチエンゲゼルシャフト | リンパ球機能抗原−１アンタゴニスト |
| ATE255888T1 (de) * | 1998-06-01 | 2003-12-15 | Ortho Mcneil Pharm Inc | Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten |
| WO2001040261A1 (en) | 1999-12-01 | 2001-06-07 | Ortho-Mcneil Pharmaceutical, Inc. | Method of diagnosing neurodegenerative disease |
| DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
| US20050075505A1 (en) | 2002-01-14 | 2005-04-07 | Gandhi Biren Jaiprakash | Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone |
| BR0309875A (pt) | 2002-05-03 | 2007-04-10 | Israel Inst For Biolog Res Isr | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto |
| US20070149543A1 (en) | 2003-01-29 | 2007-06-28 | Stockwell Brent R | Agents For Treating Neurodegenerative Diseases |
| DE102004014296A1 (de) | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen |
| DE102004014304A1 (de) | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| CA2626005A1 (en) | 2005-10-13 | 2007-10-25 | Waratah Pharmaceuticals Inc. | Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| FR2905009A1 (fr) | 2006-08-18 | 2008-02-22 | Servier Lab | Methode de criblage de composes aux proprietes anti-amyloide |
| US8614324B2 (en) | 2008-10-31 | 2013-12-24 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| US8653068B2 (en) | 2009-10-30 | 2014-02-18 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| WO2009059225A2 (en) | 2007-11-02 | 2009-05-07 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a |
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| US8580808B2 (en) | 2009-10-30 | 2013-11-12 | Pain Therapeutic, Inc. | Filamin A-binding anti-inflammatory analgesic |
| US20100279997A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
| US20100279996A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| WO2010088400A1 (en) | 2009-01-28 | 2010-08-05 | Catholic Healthcare West | Methods of diagnosing and treating neurodegenerative diseases |
| US20100280061A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| US8580809B2 (en) | 2009-10-30 | 2013-11-12 | Pain Therapeutics, Inc. | Filamin A-binding anti-inflammatory analgesic |
| US10017736B2 (en) * | 2012-07-13 | 2018-07-10 | Pain Therapeutics, Inc. | Method of inhibiting tau phosphorylation |
| WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
-
2013
- 2013-07-12 WO PCT/US2013/050368 patent/WO2014012054A1/en not_active Ceased
- 2013-07-12 JP JP2015521863A patent/JP6566867B2/ja active Active
- 2013-07-12 EP EP13816628.5A patent/EP2872899B1/en active Active
- 2013-07-15 US US13/942,326 patent/US9354223B2/en active Active
- 2013-07-18 US US13/945,612 patent/US9500640B2/en active Active
-
2016
- 2016-05-27 US US15/167,370 patent/US10222368B2/en active Active
-
2019
- 2019-02-28 US US16/289,215 patent/US11385221B2/en active Active
- 2019-07-30 JP JP2019139317A patent/JP6796168B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529802A5 (OSRAM) | ||
| US20240122910A1 (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| BR112021005606A2 (pt) | processo de produção de um composto para inibir a atividade de shp2 | |
| US20210338669A1 (en) | Oral compositions of mk2 pathway inhibitor for treatment of immune conditions | |
| JP2019218375A5 (OSRAM) | ||
| TWI684449B (zh) | 結晶型ＡＲＢ-ＮＥＰｉ複合物及其製備方法和應用 | |
| CN108473474B (zh) | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法 | |
| US20110312961A1 (en) | 2,5-Disubstituted Morpholine Orexin REceptor Antagonists | |
| CN110785417A (zh) | 膜铁转运蛋白抑制剂盐 | |
| EA020024B1 (ru) | Новые кристаллические формы и способ получения 5-({[2-амино-3-(4-карбамоил-2,6-диметилфенил)пропионил]-[1-(4-фенил-1н-имидазол-2-ил)этил]амино}метил)-2-метоксибензоевой кислоты | |
| CN108472242A (zh) | 治疗癌症的药物组合 | |
| IL302913A (en) | FGFR inhibitors and methods for their preparation and use | |
| KR102424621B1 (ko) | 로라티닙 유리 염기 수화물의 결정질 형태 | |
| JPH02117684A (ja) | フラン誘導体 | |
| WO2022109598A1 (en) | Integrin inhibitor and uses thereof | |
| BR112020008499A2 (pt) | composição farmacêutica para prevenir ou tratar leucemia mieloide aguda ou câncer de mama metastático | |
| JP2012515797A (ja) | （２ｓ，３ｒ）−ｎ−２−（（３−ピリジニル）メチル）−１−アザビシクロ［２．２．２］オクタ−３−イル）−３，５−ジフルオロベンズアミドの調製及び治療への適用 | |
| JP2018531987A5 (OSRAM) | ||
| KR20210099066A (ko) | 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체 | |
| JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
| JP2024522603A (ja) | （３ｒ）－ｎ－［２－シアノ－４－フルオロ－３－（３－メチル－４－オキソ－キナゾリン－６－イル）オキシ－フェニル］－３－フルオロ－ピロリジン－１－スルホンアミドの新規固形物 | |
| Wang et al. | Discovery and identification of Cdc37-derived peptides targeting the Hsp90–Cdc37 protein–protein interaction | |
| AU2020221247B2 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| TWI727314B (zh) | 盛格列汀的鹽、其製備方法與用途以及藥物組合物 | |
| CN111617083B (zh) | 甲氧基取代苯基酰胺类氨基嘧啶衍生物的应用 |